As per file attached.

Profit growth above 25%EBITDA margin expansionRevenue growth above 20%Results View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.1%Reaction day

₹1160.00

prior close

₹1219.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.0%+5.1% vs market

Pharmaceuticals peers, median of 164sector+0.1%+5.0% vs sector

On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.1-0.0+5.1+0.1+5.0

Next day

+10.3-0.7+11.0-0.6+10.9

+15.9-1.8+17.6-1.3+17.2

+21.7-0.7+22.4-1.4+23.1

+27.7-0.5+28.2-1.6+29.3

+34.1+0.4+33.7-0.6+34.7

+41.9-1.6+43.5-2.3+44.2

15d

+48.5+4.6+43.9+0.0+48.5

+66.3+4.6+61.7+3.0+63.3

+35.6+6.1+29.4+4.3+31.3

+37.9+10.8+27.1+8.6+29.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies reported strong FY2026 results with standalone revenue from operations of Rs 768.73 crore, up 19.3% from Rs 644.47 crore in FY2025. Net profit surged 89% to Rs 99.31 crore from Rs 52.55 crore, while consolidated net profit jumped 127% to Rs 102.78 crore. EBITDA expanded significantly to Rs 155.37 crore from Rs 90.77 crore. The Board declared a 100% dividend (Rs 10 per share) subject to shareholder approval at the 37th AGM on August 20, 2026. Key appointments include Dr. Savita Gupta as Additional Director (related party to Managing Director Mr. Pawan Chaudhary), and reappointment of Mr. Saransh Chaudhary and Dr. Gurminder Singh Bedi as Independent Directors. New cost and internal auditors were appointed for FY2026-27. The company adopted new MOA and AOA aligned with Companies Act 2013. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results.

Likely market impact

Strong operational performance with near 90% PAT growth signals robust business health. The 100% dividend payout is positive for shareholders. Related party appointment of Dr. Savita Gupta requires disclosure. Clean audit opinion with no going concern issues indicates financial stability.

By the numbersConsolidated · Q4 FY26 vs Q4 FY25

	Q4 FY26	Q4 FY25	Change
Revenue	₹259.4 Cr	₹195.0 Cr	+33.0%
Operating profit	₹56.65 Cr	₹24.28 Cr	+133.3%
Profit after tax	₹47.49 Cr	₹21.00 Cr	+126.1%
EBITDA margin	24.4%	14.9%	+9.6 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.